Delivery Order SPE2DB22D1103-SPE2DB25FTLR4

Award Date 5/1/25
Potential Completion Date 5/2/25
Potential Value $3.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic, a diabetes medication. The contract has a ceiling value of $43,484.60 and a performance period through May 6, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle for...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic, a diabetes medication. The contract has a ceiling value of $15,741.58 and a period of performance through May 5, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic, a diabetes medication. The contract has a ceiling value of $53,123.27 and a period of performance ending on May 2, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) worth up to $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a comprehensive global...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic, a medication used to treat diabetes. The contract has a ceiling value of $14,465.00 and runs through April 3, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic, a medication used to treat diabetes. The contract has a ceiling value of $13,249.82 and a performance period through May 2025. It is a firm fixed-price contract, without any set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Ozempic, a diabetes medication, with a ceiling value of $2,424.16 and a period of performance through April 2025. The contract is a firm fixed-price delivery order and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic, a diabetes medication, with a ceiling value of $24,308.59 and a period of performance through May 29, 2025. The contract is a firm fixed-price delivery order, which is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant Indefinite...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic, a diabetes medication, with a ceiling value of $4,522.56 and a performance period through April 2025. The contract is a firm fixed-price, non-set-aside award, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Ozempic, a diabetes medication, with a ceiling value of $7,271.22 and a period of performance through May 2, 2025. The contract is a firm fixed-price, non-set-aside award, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the supply of Ozempic, a diabetes medication. The contract has a ceiling value of $26,997.80 and is a firm fixed-price delivery order, with a completion date of July 9, 2025. The contract is not set-aside and is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which...
  • SPE2DB22D1103
    Indefinite Delivery Contract
  • SPE2DB22D1103-SPE2DB25FTLR4
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Ozempic, a diabetes medication, with a ceiling value of $3,264.18 and a period of performance through May 2, 2025. This order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with DLA, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle for military and government healthcare programs through December 2026. The contract is not designated as a set-aside and is open to full and open competition.

Generated 7/31/25, 9:52 AM